Skip to main content
Top
Published in: Lung 6/2017

01-12-2017

Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion

Authors: José M. Porcel, Cristina Solé, Antonieta Salud, Silvia Bielsa

Published in: Lung | Issue 6/2017

Login to get access

Abstract

Purpose

Malignant pleural effusions (MPE) may either coincide with or follow the diagnosis of a primary tumor. Whether this circumstance influences prognosis has not been well substantiated.

Methods

Retrospective review of all consecutive patients who were cared for at a Spanish university hospital during an 11-year period and received a diagnosis of MPE.

Results

Of 401 patients, the MPE was the first evidence of cancer in 265 (66%), and it followed a previously diagnosed neoplasm in 136 (34%). Lung cancer predominated in the former group (131, 50%), and breast cancer in the latter (55, 40%). MPE that were the presenting manifestation of hematological and ovarian tumors had a statistically significant survival advantage as compared to those which developed in patients from a previously known cancer (respective absolute differences of 41 and 20 months; p < 0.005).

Conclusions

In hematological and ovarian malignancies, the synchronous or metachronous diagnosis of MPE may have prognostic implications.
Literature
1.
go back to reference Porcel JM, Esquerda A, Vives M, Bielsa S (2014) Etiology of pleural effusions: analysis of more than 3000 consecutive thoracenteses. Arch Bronconeumol 50(5):161–165CrossRefPubMed Porcel JM, Esquerda A, Vives M, Bielsa S (2014) Etiology of pleural effusions: analysis of more than 3000 consecutive thoracenteses. Arch Bronconeumol 50(5):161–165CrossRefPubMed
2.
go back to reference Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A (2015) Clinical features and survival of lung cancer patients with pleural effusions. Respirology 20(4):654–659CrossRefPubMed Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A (2015) Clinical features and survival of lung cancer patients with pleural effusions. Respirology 20(4):654–659CrossRefPubMed
3.
go back to reference Light RW (2013) Pleural diseases, 6th edn. Lippincott Williams & Wilkins, Philadelphia Light RW (2013) Pleural diseases, 6th edn. Lippincott Williams & Wilkins, Philadelphia
4.
go back to reference Monte SA, Ehya H, Lang WR (1987) Positive effusion cytology as the initial presentation of malignancy. Acta Cytol 31(4):448–452PubMed Monte SA, Ehya H, Lang WR (1987) Positive effusion cytology as the initial presentation of malignancy. Acta Cytol 31(4):448–452PubMed
5.
go back to reference van de Molengraft FJ, Vooijs GP (1988) The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis. Acta Cytol 32(2):183–187PubMed van de Molengraft FJ, Vooijs GP (1988) The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis. Acta Cytol 32(2):183–187PubMed
6.
go back to reference Cellerin L, Marcq M, Sagan C, Chailleux E (2008) Pleurésies malignes révélatrices d’un cancer: comparaison des étiologies avec les pleurésies métastatiques d’un cancer connu. Rev Mal Respir 25(9):1104–1109CrossRefPubMed Cellerin L, Marcq M, Sagan C, Chailleux E (2008) Pleurésies malignes révélatrices d’un cancer: comparaison des étiologies avec les pleurésies métastatiques d’un cancer connu. Rev Mal Respir 25(9):1104–1109CrossRefPubMed
7.
go back to reference Fysh ET, Bielsa S, Budgeon CA, Read CA, Porcel JM, Maskell NA, Lee YC (2015) Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion. Chest 147(6):1629–1634CrossRefPubMed Fysh ET, Bielsa S, Budgeon CA, Read CA, Porcel JM, Maskell NA, Lee YC (2015) Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion. Chest 147(6):1629–1634CrossRefPubMed
8.
go back to reference Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, Bintcliffe OJ, Boshuizen RC, Fysh ET, Tobin CL, Medford AR, Harvey JE, van den Heuvel MM, Lee YC, Maskell NA (2014) Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 69(12):1098–1104CrossRefPubMedPubMedCentral Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, Bintcliffe OJ, Boshuizen RC, Fysh ET, Tobin CL, Medford AR, Harvey JE, van den Heuvel MM, Lee YC, Maskell NA (2014) Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 69(12):1098–1104CrossRefPubMedPubMedCentral
9.
go back to reference Porcel JM, Quirós M, Gatius S, Bielsa S (2017) Examination of cytological smears and cell blocks of pleural fluid: complementary diagnostic value for malignant effusions. Rev Clin Esp 217(3):144–148CrossRefPubMed Porcel JM, Quirós M, Gatius S, Bielsa S (2017) Examination of cytological smears and cell blocks of pleural fluid: complementary diagnostic value for malignant effusions. Rev Clin Esp 217(3):144–148CrossRefPubMed
Metadata
Title
Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion
Authors
José M. Porcel
Cristina Solé
Antonieta Salud
Silvia Bielsa
Publication date
01-12-2017
Publisher
Springer US
Published in
Lung / Issue 6/2017
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-017-0050-1

Other articles of this Issue 6/2017

Lung 6/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.